Abstract
Objectives: To describe the epidemiology of Ebstein’s anomaly in Europe and its association with maternal health and medication exposure during pregnancy. Design: Descriptive epidemiologic analysis of population-based data Setting: 15 EUROCAT Congenital Anomaly Registries in 12 European countries: population 5.6 million births 1982-2011. Participants: Cases included livebirths, fetal deaths from 20 weeks gestation, and terminations of pregnancy for fetal anomaly. Main outcome measures: Total prevalence per 10,000 births. Odds ratios for exposure to maternal illnesses / medications in the first trimester of pregnancy were calculated by comparing Ebstein’s anomaly cases to cardiac and non-cardiac malformed controls, excluding genetic syndromes; adjusted for time period and country.Results: 264 Ebstein’s anomaly cases were recorded; 81% were livebirths, 2% of which were diagnosed after the first year of life. 54% of cases Ebstein’s anomaly or a co-existing congenital anomaly was prenatally diagnosed. Total Prevalence rose over time from 0.29 (95%CI 0.20-0.41 to 0.48 (95%CI 0.40-0.57) (p
Original language | English |
---|---|
Pages (from-to) | 677-685 |
Journal | Cardiology in the Young |
Volume | 27 |
Issue number | 4 |
Early online date | 30 Aug 2016 |
DOIs | |
Publication status | Published (in print/issue) - May 2017 |
Keywords
- Ebstein’s anomaly
- Prevalence
- Antidepressants
- Psycholeptics
- Mental illness